Pyros Pharmaceuticals receives FDA approval for infantile spasms drug
This new treatment is specifically indicated as a monotherapy for paediatric patients aged one month to two years with IS, provided the potential benefits justify the risk of
Rosemont Pharmaceuticals, a developer of liquid medicines, has announced the acquisition of Pharma-Data, a research and development organisation based in Lavrion, Greece, enhancing its ability to develop products for worldwide market.
These treatments, known as Folding Interfering Degraders (FIDs), target the protein folding process to induce the degradation of cancer-related proteins. The collaboration will leverage Sibylla’s Pharmacological Protein Inactivation